Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Velcade sNDA Submitted For Mantle Cell Lymphoma Indication

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Millennium/J&J injection demonstrated a 33% overall response rate among treated patients with the aggressive cancer.

You may also be interested in...



Millennium Inks Velcade Co-Promotion Deal With J&J In U.S.

Agreement provides for two-year co-promotion deal with J&J’s Ortho Biotech subsidiary.

Millennium Inks Velcade Co-Promotion Deal With J&J In U.S.

Agreement provides for two-year co-promotion deal with J&J’s Ortho Biotech subsidiary.

J&J/Millenium Studying Velcade/Rituxan Combo For Treatment Of NHL

Millennium and development partner Johnson & Johnson have initiated a Phase III trial evaluating Velcade (bortezomib) in combination with Genentech/Biogen Idec's Rituxan (rituximab) in the treatment of refractory follicular lymphoma, a subtype of non-Hodgkin's lymphoma, the companies announced April 18

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

‘Unbalanced’ EU HTA Timelines Exacerbated By Rare Disease & Cancer Drugs

National Drug Stockpiles Create ‘False Sense Of Security’

Patent Office Issues Proposed Rule For Rarely Successful Director Review Requests

Medicare Spending Forecast For Leqembi Reflects CMS Angst About Alzheimer’s Drug Costs

See All
UsernamePublicRestriction

Register

PS064475

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By